Recent blogs have focused on US Pharma Pricing practices. Since Turing Pharmaceuticals gouged the US market with astronomical price hikes for an old drug which was in short supply, the system has finally woken up. Not only have Hilary Clinton and Bernie Saunders been exercised but now House Democrats and the hill in general are energised as they consider how lucrative and frequent these price hikes have been, without any apparent justification beyond opportunism.
Although the US is a different planet to the rest of the world when it comes to healthcare, one thing is common. When government gets exercised at the practices of select companies or industries, the long term implications for the sector, companies and industry are not good.
Valeant which has had a stellar run for the past 2 years has seen its share price implode due to the momentum which has hit the frequent price raisers. Along with the market getting jittery, regulatory reviews and "events" have overtaken the company. Their relationship with Philidor a specialty pharmacy group has had to be reviewed (ended), over recriminations about practices.
Keep watching this space. Once the tide turns, its hard to turn back the sea.